Clinical Research Directory
Browse clinical research sites, groups, and studies.
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Trisha Wise-Draper
Summary
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
Official title: An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2018-10-23
Completion Date
2024-12-01
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
Durvalumab
Two hour infusion
Cetuximab
Two hour infusion for loading dose followed by weekly one hour infusion
Locations (1)
UC Health
Cincinnati, Ohio, United States